

**Arbutus Biopharma Corporation 701 Veterans Circle  
Warminster, Pennsylvania 18974**

November 16, 2021

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549

Re: Arbutus Biopharma Corporation  
Registration Statement on Form S-3  
Filed November 4, 2021  
File No. 333-260782  
Request for Acceleration of Effective Date

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Arbutus Biopharma Corporation hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the "Registration Statement") to become effective on November 18, 2021, at 4:00 p.m. Eastern Standard Time, or as soon thereafter as is practicable.

Once the Registration Statement has been declared effective, please orally confirm that event with Stephen M. Nicolai of Hogan Lovells US LLP at (267) 675-4642.

**ARBUTUS BIOPHARMA CORPORATION**

By: /s/ David C. Hastings  
Name: David C. Hastings  
Title: Chief Financial Officer